Waters New Bioseparations Tools Accelerate and Improve Development of RNA-based Vaccines and Therapies Using LC-MS Analysis
Waters (NYSE: WAT) has introduced new bioseparations tools to accelerate and improve the development of RNA-based pharmaceuticals. The comprehensive set includes:
1. Novel digestion enzymes (RapiZyme MC1 and RapiZyme Cusativin) for complete RNA sequence coverage.
2. LC-MS-grade reagents (IonHance HFIP) to increase sensitivity and improve detection accuracy.
3. waters_connect MAP Sequence software for semi-automated workflows, reducing data processing time.
These tools simplify large molecule RNA analysis, supporting the development of mRNA vaccines, personalized cancer therapies, and drugs for genetic disorders. The new products aim to enhance sequence confirmation, modification analysis, and overall characterization of complex RNA molecules, potentially accelerating therapeutic development and lowering barriers for LC-MS non-experts.
Waters (NYSE: WAT) ha introdotto nuovi strumenti di bioseparazione per accelerare e migliorare lo sviluppo di farmaceutici a base di RNA. Il set completo include:
1. Nuove enzimi di digestione (RapiZyme MC1 e RapiZyme Cusativin) per una copertura completa delle sequenze RNA.
2. Reagenti di qualità LC-MS (IonHance HFIP) per aumentare la sensibilità e migliorare l'accuratezza di rilevamento.
3. Software waters_connect MAP Sequence per flussi di lavoro semi-automatici, riducendo i tempi di elaborazione dei dati.
Questi strumenti semplificano l'analisi di RNA a grandi molecole, supportando lo sviluppo di vaccini a mRNA, terapie personalizzate per il cancro e farmaci per disturbi genetici. I nuovi prodotti mirano a migliorare la conferma delle sequenze, l'analisi delle modifiche e la caratterizzazione generale di complesse molecole di RNA, accelerando potenzialmente lo sviluppo terapeutico e abbattendo le barriere per i non esperti in LC-MS.
Waters (NYSE: WAT) ha introducido nuevas herramientas de bioseparación para acelerar y mejorar el desarrollo de fármacos a base de RNA. El conjunto integral incluye:
1. Nuevas enzimas de digestión (RapiZyme MC1 y RapiZyme Cusativin) para una cobertura completa de las secuencias de RNA.
2. Reactivos de calidad LC-MS (IonHance HFIP) para aumentar la sensibilidad y mejorar la precisión de detección.
3. Software waters_connect MAP Sequence para flujos de trabajo semi-automáticos, reduciendo el tiempo de procesamiento de datos.
Estas herramientas simplifican el análisis de RNA de grandes moléculas, apoyando el desarrollo de vacunas de mRNA, terapias personalizadas para el cáncer y medicamentos para trastornos genéticos. Los nuevos productos tienen como objetivo mejorar la confirmación de secuencias, el análisis de modificaciones y la caracterización general de complejas moléculas de RNA, acelerando potencialmente el desarrollo terapéutico y reduciendo las barreras para los no expertos en LC-MS.
Waters (NYSE: WAT)는 RNA 기반 의약품 개발을 가속화하고 개선하기 위해 새로운 바이오분리 도구를 도입했습니다. 이 포괄적인 세트에는 다음이 포함됩니다:
1. 새로운 소화 효소 (RapiZyme MC1 및 RapiZyme Cusativin)로 RNA 서열을 완전히 커버합니다.
2. LC-MS급 시약 (IonHance HFIP)로 감도를 높이고 탐지 정확도를 개선합니다.
3. waters_connect MAP Sequence 소프트웨어로 반자동화된 워크플로우를 통해 데이터 처리 시간을 단축합니다.
이 도구들은 대분자 RNA 분석을 간소화하여 mRNA 백신, 개인 맞춤형 암 요법 및 유전적 질환 치료제를 개발하는 데 도움을 줍니다. 새로운 제품은 복잡한 RNA 분자의 서열 확인, 수정 분석 및 전반적인 특성화를 개선하여 치료 개발을 가속화하고 LC-MS 비전문가의 장벽을 낮추는 것을 목표로 합니다.
Waters (NYSE: WAT) a introduit de nouveaux outils de bio-séparation pour accélérer et améliorer le développement de pharmaceutiques à base d'ARN. L'ensemble complet comprend :
1. Nouveaux enzymes de digestion (RapiZyme MC1 et RapiZyme Cusativin) pour une couverture complète des séquences ARN.
2. Réactifs de qualité LC-MS (IonHance HFIP) pour augmenter la sensibilité et améliorer l’exactitude de détection.
3. Logiciel waters_connect MAP Sequence pour des flux de travail semi-automatisés, réduisant le temps de traitement des données.
Ces outils simplifient l'analyse de l'ARN à grande molécule, soutenant le développement de vaccins à base d'ARNm, de thérapies personnalisées contre le cancer et de médicaments pour des troubles génétiques. Les nouveaux produits visent à améliorer la confirmation des séquences, l'analyse des modifications et la caractérisation globale de molécules d'ARN complexes, pouvant potentiellement accélérer le développement thérapeutique et abaisser les barrières pour les non-experts en LC-MS.
Waters (NYSE: WAT) hat neue Bio-Trennwerkzeuge eingeführt, um die Entwicklung von RNA-basierten Arzneimitteln zu beschleunigen und zu verbessern. Das umfassende Set umfasst:
1. Neue Verdauungsenzyme (RapiZyme MC1 und RapiZyme Cusativin) für eine vollständige RNA-Sequenzabdeckung.
2. LC-MS-qualitätsreagenzien (IonHance HFIP), um die Empfindlichkeit zu erhöhen und die Nachweisgenauigkeit zu verbessern.
3. w waters_connect MAP Sequence-Software für halbautomatisierte Arbeitsabläufe, die die Datenverarbeitungszeit reduziert.
Diese Werkzeuge vereinfachen die Analyse von RNA großen Molekülen und unterstützen die Entwicklung von mRNA-Impfstoffen, personalisierten Krebstherapien und Medikamenten gegen genetische Erkrankungen. Die neuen Produkte zielen darauf ab, die Sequenzbestätigung, Modifikationsanalyse und die allgemeine Charakterisierung komplexer RNA-Moleküle zu verbessern, was potenziell die therapeutische Entwicklung beschleunigt und Hürden für LC-MS-Nicht-Experten abbaut.
- Introduction of new bioseparations tools for RNA-based pharmaceutical development
- Novel enzymes provide complete RNA sequence coverage for more confident characterization
- New LC-MS-grade reagents increase sensitivity and improve detection accuracy
- New software reduces data processing time over manual techniques
- Tools simplify confirmation of sequence and modifications of RNA molecules
- Potential to accelerate RNA therapeutic development and lower barriers for LC-MS non-experts
- None.
Insights
Waters 's introduction of new bioseparations tools for RNA analysis represents a significant advancement in the field of RNA therapeutics. These tools address critical challenges in the development of mRNA vaccines, personalized cancer treatments and CRISPR therapies.
The key innovations include:
- Novel digestion enzymes (RapiZyme MC1 and Cusativin) for improved RNA sequence coverage
- LC-MS-grade reagents (IonHance HFIP) for enhanced sensitivity and accuracy
- waters_connect MAP Sequence software for accelerated data processing
These advancements could potentially accelerate the development timeline for RNA-based therapeutics and improve their characterization, which is important for ensuring safety and efficacy. The simplified workflow and improved analytical capabilities may also lower barriers to entry for companies developing RNA therapies, potentially expanding the competitive landscape.
For investors, this positions Waters as a key player in the rapidly growing RNA therapeutics market, which is projected to reach
Waters' new RNA analytical tools are well-positioned to capitalize on the booming RNA therapeutics market. The global mRNA therapeutics market alone is expected to grow at a CAGR of
Key market drivers that align with Waters' innovations include:
- Increasing demand for personalized medicine
- Growing investment in RNA-based drug development
- Rising need for more efficient and accurate analytical tools
Waters' comprehensive solution, combining enzymes, reagents and software, addresses the entire workflow, potentially increasing customer loyalty and creating barriers to entry for competitors. This integrated approach could lead to higher profit margins and recurring revenue streams from consumables and software subscriptions.
The collaboration with Quality Assistance S.A. and the upcoming presentations at industry events demonstrate Waters' commitment to thought leadership in this space, which could further strengthen its market position and attract new customers in the pharmaceutical and biotech sectors.
News Summary:
- Waters new LC-MS grade reagents, enzymes, and software simplify large molecule RNA analysis to accelerate and improve development of mRNA vaccines, personalized cancer therapies, and innovative drugs for genetic disorders.
- Novel digestion enzymes deliver complete RNA sequence coveragei for more confident characterization, while new LC-MS-grade reagents increase sensitivity and improve detection accuracy of RNA components.ii
- New waters_connect™ MAP Sequence software accelerates RNA oligonucleotide mapping using semi-automated workflows that reduce data processing time over manual techniques, enabling routine monitoring of key product attributes.
Large molecule RNA (ribonucleic acid) therapeutics represent some of the most exciting and potentially life-saving developments in pharmaceuticals today. They include new and more effective vaccines for diseases like COVID-19, personalized cancer treatments, as well as emerging CRISPR RNA therapies that address challenging genetic conditions, such as sickle cell anemia.
"As RNA-based therapies are prepared for widespread use, more direct composition measurements are needed to ensure stability, safety, and effectiveness for patients," said Erin Chambers, Vice President, Consumables and Lab Automation at Waters Corporation. "The combination of Waters enzymes, reagents, and software are specially designed to simplify the confirmation of sequence and modifications of complex molecules. These analytical tools can accelerate RNA therapeutic development and lower barriers for use by LC-MS non-experts."
"As innovators looking to help our customers advance nucleic acid-based therapies and reduce the burden of serious diseases, we are always seeking new technologies to improve characterization and accelerate development," said Arnaud Delobel, PhD, R&D and Innovation Director at Quality Assistance S.A. and beta tester of the Waters RNA analytical tools. "Waters new enzymes efficiently digest mRNA and sgRNA with short incubation times and data processing in MAP Sequence allows the user to obtain reproducible results quickly with confidence."
The Waters RNA analytical tools include:
- Enzymes: Two novel enzymes, RapiZyme™ MC1 and RapiZyme Cusativin, are used in a simplified three-step protocol that provides complete LC-MS sequence coverage over traditional digestion methods enabling more confident characterization of RNA molecules.iii
- Reagents: IonHance™ HFIP, an LC-MS-grade reagent, is formulated to improve ionization and delivers increased spectral clarity and detection accuracy of RNA components.
- Software: New MAP Sequence application on the waters_connect software platform simplifies RNA LC-MS oligo mapping workflows to accelerate analysis and data processing time over manual techniques using spreadsheets.
Used together within a workflow, the tools generate an LC-MS fingerprint to confirm product identity, purity, and efficacy. The tools improve sequence coverage, LC-MS spectral data quality, and data interpretation. Supported by the compliance-ready waters_connect software platform, these tools help transition LC and LC-MS-based digestion analysis from discovery and development to release and at-line process analytical testing.
Waters RapiZyme RNAses and IonHance HFIP are now available. The new MAP Sequence App on waters_connect software will be available on October 18, 2024.
Additional Resources
- Learn more about the Waters RNA Analytical Tools
- Listen to our webinar "Cracking the Code: Analyzing mRNA and sgRNA with Advanced Enzymes, Mass Spectrometry, and Informatics on Oct. 16 at 11:00am ET
- Join Waters at the PharmSci 360 conference for an expert session on "Oligo Mapping of Large RNA Therapeutics by Novel Enzyme Specificities" with Dr. Bala Addepalli, Waters Director, R&D New Modalities Portfolio on Oct. 21, at 11:00am ET
- Follow and connect with Waters via LinkedIn, Twitter, and Facebook
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. With approximately 7,500 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.
Waters, Rapizyme, IonHance, and waters_connect are trademarks of Waters Technologies Corporation.
Contact:
Janice Foley
Senior Public Relations Manager, Corporate Communications
Waters Corporation
janice_foley@waters.com
+1.617.823.5555
i
ii IonHance HFIP reagents are certified to contain less than 100 ppb sodium and less than 100 ppb potassium content, resulting in reduced adduct formation and improved sensitivity of RNA detection compared to commercially available HFIP. Waters Application Note 720008540EN: "Evaluating IonHance Hexafluoroisopropanol (HFIP) for Enhanced LC-MS Oligonucleotide Analysis"
iii Waters RapiZyme RNase protocol simplifies sample preparation with three steps including reagent preparation, RNA digestion, and heat inactivation without the need to add chemical denaturants and enzyme inhibitors.
View original content to download multimedia:https://www.prnewswire.com/news-releases/waters-new-bioseparations-tools-accelerate-and-improve-development-of-rna-based-vaccines-and-therapies-using-lc-ms-analysis-302272290.html
SOURCE Waters Corporation
FAQ
What new products did Waters (WAT) introduce for RNA analysis?
How do Waters' new RNA analytical tools benefit pharmaceutical development?
When will Waters 's (WAT) new MAP Sequence App be available?
What advantages do Waters' new enzymes offer for RNA analysis?
